NCT05818553Phase 2, phase 3Active not recruiting

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

Study sponsor: Praxis Precision Medicines

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-11-12Actual
Enrollment · participants77Estimated
Source updated2026-01-29Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To assess the effect of PRAX-562 on the frequency of countable motor seizures in pediatric participants with DEEs. After: Measure: PART A (Cohorts 1 and 2) RDB: To evaluate the safety and tolerability of PRAX 562 in pediatric participants with SCN2A- and SCN8A- DEEs Measure: PART B (Cohorts 1 and 2) OLE: To evaluate the long-term safety and tolerability of PRAX-562 in pediatric participants with DEEs.

Planned enrollment decreased by 23 participants

Before: 100 participants (planned). After: 77 participants (planned).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 23 Mar 2026. After: 12 Nov 2025.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview